Turning stats into outcomes
January 14, 2013
Shares in ArQule dropped more than 20% after the firm and its partner Daiichi Sankyo unveiled disappointing results from a Phase II trial of their experimental colorectal cancer drug tivantinib.
August 31, 2012
Bayer and partner Onyx Pharmaceuticals has filed regorafenib in the USA for a second indication, that of gastrointestinal stromal tumours
April 11, 2011
A record 887 drugs and vaccines for various cancers are now in clinical trials or awaiting US FDA review, well over double the number that were in the pipeline just six years ago, says a new US report.
PharmaTimes 2013 Copyright | RSS Feed Subscriptions